%0 Journal Article
%T ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-¦Â copathology
%A Athanasios Dimitriadis
%A Carolin Koriath
%A James B. Rowe
%A Jason D. Warren
%A John Collinge
%A Jonathan D. Rohrer
%A Jonathan M. Schott
%A Julie Williams
%A Nick C. Fox
%A Nicola Denning
%A Ronald Druyeh
%A Tammaryn Lashley
%A William Taylor
%J Archive of "Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring".
%D 2019
%R 10.1016/j.dadm.2019.01.010
%X Apolipoprotein E (ApoE) is the most important genetic risk factor for Alzheimer's disease (AD), with ApoE4 thought to enhance and accelerate amyloid-¦Â (A¦Â) pathology. ApoE4 has recently been described to increase neurodegeneration in a mouse model of frontotemporal dementia (FTD), in vitro, and in patients, demonstrating that ApoE4 modifies tauopathy independently of A¦Â. This raises the question whether ApoE genotype also modifies the clinical phenotype in patients with FTD with tau pathology
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430720/